Title	Response assessment
Number of Patients Screened	65
Number of Patients Enrolled	44
Number of Patients Evaluable for Toxicity	44
Number of Patients Evaluated for Efficacy	44
Evaluation Method	RECIST 1.1
Response Assessment CR	n = 1 (2.3%)
Response Assessment PR	n = 9 (20.5%)
Response Assessment SD	n = 15 (34.1%)
Response Assessment PD	n = 8 (18.2%)
Response Assessment OTHER	n = 11 (25%)
(Median) Duration Assessments PFS	4.0 Months, CI: 2.3–8.5
(Median) Duration Assessments TTP	9.8 Months, CI: 8.6–19.5
(Median) Duration Assessments OS	10.6 Months, CI: 6.9–12.7
Outcome Notes	ORR was observed in 10 patients (22.7%). CBR was observed in 25 patients (56.8%).